BENICAR

Compare BENICAR  to:
Compare
Compare

Generic Name for BENICAR

Olmesartan medoxomil 5mg, 20mg, 40mg; tabs.

Legal Classification:

Rx

Pharmacological Class for BENICAR

Angiotensin II receptor blocker.

Manufacturer of BENICAR

Daiichi Sankyo

Indications for BENICAR

Hypertension.

Adult dose for BENICAR

Monotherapy, not volume-depleted: initially 20mg once daily; may increase to max 40mg once daily after 2 weeks. Volume depleted (eg, concomitant diuretic): consider lower initial dose.

Children's dosing for BENICAR

Not recommended.

Contraindications for BENICAR

Pregnancy (Cat.D in 2nd and 3rd trimesters).

Precautions for BENICAR

Correct salt/volume depletion before beginning therapy, or monitor closely. Severe CHF. Renal artery stenosis. Pregnancy (Cat.C in 1st trimester). Nursing mothers: not recommended.

Interactions for BENICAR

Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes.

Adverse Reactions for BENICAR

Dizziness, rhabdomyolysis (rare).

How is BENICAR supplied?

Tabs 5mg—30
20mg, 40mg—30, 90

Related Disease:

Hypertension

Related Resources

FDA warns of reduced Plavix efficacy in poor metabolizers

March 15, 2010

The FDA has notified healthcare professionals and patients that a Boxed Warning has been added to the Plavix (clopidogrel tablets, from Bristol-Myers Squibb and Sanofi) Prescribing Information to include information about reduced Plavix efficacy in patients who are poor metabolizers of Plavix.

Benicar gains expanded indication for treatment of hypertension in children

February 11, 2010

The FDA has approved Benicar (olmesartan medoxomil tablets, from Daiichi Sankyo) for the treatment of hypertension in children and adolescents 6-16 years of age.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Cleviprex injection recalled due to presence of particulate matter

December 17, 2009

The FDA and The Medicines Company have notified healthcare professionals of a voluntary nationwide recall of 11 lots of Cleviprex (clevidipine butyrate) injection emulsion due to the presence of visible particulate matter observed in some vials.

Clonidine ER Suspension and Clonidine ER Tablets approved

December 07, 2009

Tris Pharma announced that the FDA has approved Clonidine ER suspension and Clonidine ER tablets, both of which utilize its proprietary OralXR+ platform technology to allow for once daily dosing.